Patents by Inventor John C. Fiddes

John C. Fiddes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Recombinant fibroblast growth factor analogs
    Patent number: 7186526
    Abstract: The DNA sequences encoding analogs of human acidic and basic fibroblast growth factors (FGF) can be recombinantly expressed to obtain practical amounts of proteins useful in effecting both pathologies related to persistent angiogenesis and wound healing and related tissue repair.
    Type: Grant
    Filed: June 13, 2005
    Date of Patent: March 6, 2007
    Assignee: Scios, Inc.
    Inventors: John C. Fiddes, Judith A. Abraham, Andrew Protter
  • Recombinant fibroblast growth factors
    Publication number: 20030040042
    Abstract: The DNA sequences encoding analogs of human acidic and basic fibroblast growth factors (FGF) can be recombinantly expressed to obtain practical amounts of proteins useful in effecting both pathologies related to persistent angiogenesis and wound healing and related tissue repair.
    Type: Application
    Filed: July 9, 2001
    Publication date: February 27, 2003
    Inventors: John C. Fiddes, Judith A. Abraham, Andrew Protter
  • Human basic fibroblast growth factor analog
    Patent number: 6294359
    Abstract: The DNA sequences encoding analogs of human acidic and basic fibroblast growth factors (FGF) can be recombinantly expressed to obtain practical amounts of proteins useful in effecting both pathologies related to persistent angiogenesis and wound healing and related tissue repair.
    Type: Grant
    Filed: June 16, 1998
    Date of Patent: September 25, 2001
    Assignee: Scios Inc.
    Inventors: John C. Fiddes, Judith A. Abraham, Andrew Protter
  • Compositions and methods for the prevention and treatment of oral mucositis
    Patent number: 6025326
    Abstract: The present invention provides methods and compositions suitable for treating oral mucositis in animals, including humans, with antimicrobial peptides such as protegrin peptides.
    Type: Grant
    Filed: November 21, 1996
    Date of Patent: February 15, 2000
    Assignee: IntraBiotics Pharmaceuticals, Inc.
    Inventors: Deborah A. Steinberg, De Hwa Chao, David J. Loury, Roger Cherng Fu, Chee Liang Gu, Conway C. Chang, John C. Fiddes
  • Human basic fibroblast growth factor analog
    Patent number: 5859208
    Abstract: A human basic fibroblast growth factor (FGF) protein analog wherein the cysteine at positions 78 and 96 is replaced by serine, and said analog exhibits the biological activity of native, human basic FGF.The DNA sequences encoding analogs of human acidic and basic fibroblast growth factors (FGF) can be recombinantly expressed to obtain practical amounts of proteins useful in effecting both pathologies related to persistent angiogenesis and wound healing and related tissue repair.
    Type: Grant
    Filed: February 12, 1990
    Date of Patent: January 12, 1999
    Inventors: John C. Fiddes, Judith A. Abraham, Andrew A. Protter
  • Recombinant human basic fibroblast growth factor
    Patent number: 5604293
    Abstract: The DNA sequences encoding human and bovine acidic and basic fibroblast growth factors (FGF) can be recombinantly expressed to obtain practical amounts of proteins useful in effecting wound healing and related tissue repair.
    Type: Grant
    Filed: April 1, 1994
    Date of Patent: February 18, 1997
    Assignee: Scios Inc.
    Inventors: John C. Fiddes, Judith A. Abraham
  • Methods of producing recombinant fibroblast growth factors
    Patent number: 5514566
    Abstract: Disclosed herein are the DNA sequences encoding human and bovine acidic and basic fibroblast growth factors (FGF). Expression of these sequences results in practical amounts of proteins useful in effecting wound healing.
    Type: Grant
    Filed: April 5, 1995
    Date of Patent: May 7, 1996
    Assignee: SCIOS Nova Inc.
    Inventors: John C. Fiddes, Judith A. Abraham
  • DNA encoding human recombinant basic fibroblast growth factor
    Patent number: 5439818
    Abstract: Disclosed herein are the DNA sequences encoding human and bovine acidic and basic fibroblast growth factors (FGF). Expression of these sequences results in practical amounts of proteins useful in effecting wound healing.
    Type: Grant
    Filed: December 16, 1985
    Date of Patent: August 8, 1995
    Assignee: Scios Nova Inc.
    Inventors: John C. Fiddes, Judith A. Abraham
  • DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF.sub.120 and hVEGF.sub.121
    Patent number: 5219739
    Abstract: Isolated DNA sequences, expression vectors and transformant cells are provided which allow for the large scale production of vascular endothelial cell growth factor. The vascular endothelial cell growth factor is useful in the treatment of wounds in which neovascularization or reendothelialization is required for healing.
    Type: Grant
    Filed: July 27, 1990
    Date of Patent: June 15, 1993
    Assignee: Scios Nova Inc.
    Inventors: Edmund G. Tischer, Judith A. Abraham, John C. Fiddes, Richard L. Mitchell
  • Production of vascular endothelial cell growth factor
    Patent number: 5194596
    Abstract: There is described an isolated vascular endothelial cell growth factor selected from the group consisting of bovine vascular endothelial cell growth factor of 120 amino acids and human vascular endothelial cell growth factor of 121 amino acids. The vascular endothelial cell growth factor is useful in the treatment of wounds in which neovascularization or reendothelialization is required for healing.
    Type: Grant
    Filed: December 14, 1989
    Date of Patent: March 16, 1993
    Assignee: California Biotechnology Inc.
    Inventors: Edmund G. Tischer, Judith A. Abraham, John C. Fiddes, Richard L. Mitchell